SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
+8.02%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$520M
AUM Growth
+$520M
(+8.9%)
Cap. Flow
+$22.6M
Cap. Flow
% of AUM
4.34%
Top 10 Holdings %
Top 10 Hldgs %
74.31%
Holding
43
New
3
Increased
1
Reduced
6
Closed
1
Top Buys
| 1 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$34.9M |
| 2 |
ARTV
Artiva Biotherapeutics, Inc. Common Stock
ARTV
|
$4.51M |
| 3 |
Jasper Therapeutics
JSPR
|
$1.12M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$891K |
Top Sells
| 1 |
Arcellx
ACLX
|
$8.35M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$4.38M |
| 3 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$3.32M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$1.06M |
| 5 |
Janux Therapeutics
JANX
|
$1.02M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRGX
1
DELISTED
CARGO Therapeutics
CRGX
| $81.5M | 15.66% | 4,415,689 | – | – |
|
2
Mineralys Therapeutics
MLYS
$1.03B
| $61.5M | 11.81% | 5,074,916 | – | – |
|
3
Scholar Rock
SRRK
$3.14B
| $54.4M | 10.45% | 6,788,609 | – | – |
|
4
Neurogene
NGNE
$264M
| $53.2M | 10.22% | 1,267,790 | – | – |
|
|
ALMS
5
Alumis Inc. Common Stock
ALMS
$479M
| $34.9M | 6.71% | +3,266,498 | New | +$34.9M |
|
|
6
Arcellx
ACLX
$3.85B
| $29.5M | 5.68% | 353,641 -100,000 | -22% | -$8.35M |
|
|
LENZ
7
LENZ Therapeutics
LENZ
$1.1B
| $28.7M | 5.51% | 1,208,473 | – | – |
|
8
Nkarta
NKTX
$151M
| $17M | 3.27% | 3,768,035 | – | – |
|
|
CLYM
9
Climb Bio, Inc. Common Stock
CLYM
$151M
| $13.3M | 2.55% | 2,609,114 -652,279 | -20% | -$3.32M |
|
|
AVDL
10
Avadel Pharmaceuticals
AVDL
$1.43B
| $12.7M | 2.44% | 967,527 | – | – |
|
11
Zymeworks
ZYME
$1.12B
| $12.6M | 2.41% | 1,000,000 | – | – |
|
|
SLRN
12
DELISTED
ACELYRIN
SLRN
| $12.4M | 2.39% | 2,523,022 | – | – |
|
|
CTNM
13
Contineum Therapeutics
CTNM
$293M
| $11.3M | 2.17% | 588,816 -1 | -0% | -$19 |
|
|
14
Jasper Therapeutics
JSPR
$45.5M
| $11M | 2.11% | 584,642 +59,642 | +11% | +$1.12M |
|
|
ABVX
15
Abivax
ABVX
$6.12B
| $9.79M | 1.88% | 850,000 | – | – |
|
16
Rhythm Pharmaceuticals
RYTM
$6.85B
| $9.04M | 1.74% | 172,647 | – | – |
|
|
INZY
17
DELISTED
Inozyme Pharma
INZY
| $8.17M | 1.57% | 1,562,500 | – | – |
|
18
Sutro Biopharma
STRO
$72.7M
| $7.6M | 1.46% | 2,196,814 | – | – |
|
19
Leap Therapeutics
LPTX
$12M
| $6.28M | 1.21% | 2,442,352 | – | – |
|
20
Gossamer Bio
GOSS
$562M
| $6.05M | 1.16% | 6,130,268 | – | – |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| $5.62M | 1.08% | 195,225 -152,275 | -44% | -$4.38M |
|
22
Tango Therapeutics
TNGX
$747M
| $4.85M | 0.93% | 630,000 | – | – |
|
|
ARTV
23
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $4.51M | 0.87% | +291,666 | New | +$4.51M |
|
|
SYRS
24
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.84M | 0.74% | 1,786,427 | – | – |
|
25
IO Biotech
IOBT
$104M
| $3.82M | 0.73% | 3,640,015 | – | – |
|